Evotec at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Evotec brings 3 presentations to ESGCT 2026 in Hamburg, its home city. Its contributions centre on off-the-shelf cell therapies grown from induced pluripotent stem cells and shielded from immune rejection, aimed at fibrosis and liver cancer. It also gives an industry view of advanced therapy development under European pharmaceutical reform.
| Organization | ESGCT 2026 Attendance |
|---|---|
Evotec Hamburg, Germany | |
Drug discovery and development partner offering research, development and manufacturing services to pharma and biotech, including cell therapy work. | Poster Wed Oct 28 1:30pm–3:30pm Immune-shielded iPSC-derived macrophages for off-the-shelf cell therapy of fibrosis Poster Wed Oct 28 1:30pm–3:30pm Off-the-shelf immune-shielded iPSC-derived CAR γδ T cells as novel cell therapy to treat hepatocellular carcinoma Talk Fri Oct 30 12:05pm–1:00pm ATMP development in a changing Europe: An industry perspective on the EU Pharmaceutical Reform Manufacturing, CMC and access |
Instantly find 20 buyers from Evotec
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction